Twist Bioscience Corporation (TWST) Tops Q4 EPS by 16c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2020 Financial Results
November 23, 2020 7:01 AM EST-- Fiscal 2020 Revenues of $90.1M; Increase of 66% over $54.4M in Fiscal 2019 --
-- Strong Growth in Synthetic Biology, NGS Businesses --
-- Twist Biopharma Established 13 Partnerships, 8 with Milestones and/or Royalties in FY20 --
-- Expect Revenue of $110M to $118M for Fiscal 2021 --
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business... More
